Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

ABSTRACT Several different methods have been developed to quantitate neutralizing antibody responses to human papillomaviruses (HPVs), including in vivo neutralization assays, in vitro pseudoneutralization assays, competitive radioimmunoassays (cRIAs), and enzyme-linked immunosorbent assays. However, each of these techniques possesses one or more limitations that preclude testing large numbers of patient sera for use in natural history studies and large vaccine clinical trials. We describe here a new multiplexed assay, by using the Luminex Laboratory MultiAnalyte Profiling (LabMAP3) assay system, that can simultaneously quantitate neutralizing antibodies to human papillomavirus types 6, 11, 16, and 18 in 50 μl of serum. The HPV-Luminex competitive immunoassay measures titers of polyclonal antibodies in serum capable of displacing phycoerythrin-labeled detection monoclonal antibodies binding to conformationally sensitive, neutralizing epitopes on the respective virus-like particles. This competitive Luminex immunoassay was found to be as sensitive, accurate, and precise as the currently used cRIAs. An effective HPV vaccine will most likely require several distinct genotypes to protect against multiple cancer causing papillomaviruses. The HPV-Luminex immunoassay should prove to be a useful tool in simultaneously quantitating antibody immune responses to multiple HPV genotypes for natural history infection studies and for monitoring the efficacy of prospective vaccines.

[1]  R. W. Wright,et al.  Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. , 1986, Analytical biochemistry.

[2]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[3]  R. Woods,et al.  Characterization of a Major Neutralizing Epitope on Human Papillomavirus Type 16 L1 , 1999, Journal of Virology.

[4]  D. Lowy,et al.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  David R. Scott,et al.  Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. , 1995, The Journal of infectious diseases.

[6]  T. Baker,et al.  Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. , 1991, Biophysical journal.

[7]  T. Sasagawa,et al.  Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. , 1995, Virology.

[8]  R. Roden,et al.  Mucosal but Not Parenteral Immunization with Purified Human Papillomavirus Type 16 Virus-Like Particles Induces Neutralizing Titers of Antibodies throughout the Estrous Cycle of Mice , 1999, Journal of Virology.

[9]  K. Jansen,et al.  Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae. , 1996, Gene.

[10]  C. Meijer,et al.  The presence of persistent high‐risk hpv genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months , 1995, International journal of cancer.

[11]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[12]  R. Mcglennen.  Human papillomavirus oncogenesis. , 2000, Clinics in laboratory medicine.

[13]  M. Rosolowsky,et al.  Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. , 1995, Virology.

[14]  D. Lowy,et al.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection , 1995, Journal of virology.

[15]  K. Jansen,et al.  Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus‐like particle IgG concentration , 1997, Journal of medical virology.

[16]  R Bellisario,et al.  Simultaneous measurement of antibodies to three HIV-1 antigens in newborn dried blood-spot specimens using a multiplexed microsphere-based immunoassay. , 2001, Early human development.

[17]  C. Wheeler,et al.  Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. , 2001, The Journal of infectious diseases.

[18]  N. Christensen,et al.  Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11 , 1990, Journal of virology.

[19]  T. Martins.  Development of Internal Controls for the Luminex Instrument as Part of a Multiplex Seven-Analyte Viral Respiratory Antibody Profile , 2002, Clinical and Vaccine Immunology.

[20]  V. Moreno,et al.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.

[21]  K. Jansen,et al.  Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. , 2001, Vaccine.

[22]  H. Hausen.  Viruses in human cancers , 1991 .

[23]  J. W. Pickering,et al.  A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. , 2002, American journal of clinical pathology.

[24]  N. Christensen,et al.  Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. , 1996, Virology.

[25]  K. Jansen,et al.  Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. , 1999, Protein expression and purification.

[26]  G. Grindlay,et al.  Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. , 1991, Virology.

[27]  M. Hagensee,et al.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.

[28]  W. Phelps,et al.  Antiviral Therapy for Human Papillomaviruses: Rationale and Prospects , 1995, Annals of Internal Medicine.

[29]  K. Jansen,et al.  Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. , 1996, The Journal of general virology.

[30]  K. Jansen,et al.  Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. , 2000, Virology.

[31]  R. Schlegel,et al.  Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. , 1994, Virology.

[32]  R. Zaino,et al.  Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata , 1985, Nature.

[33]  J. Ferlay,et al.  Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden , 1993, International journal of cancer.

[34]  R J Fulton,et al.  Advanced multiplexed analysis with the FlowMetrix system. , 1997, Clinical chemistry.

[35]  P. Coursaget,et al.  Human papillomavirus vaccines. , 1999, Seminars in cancer biology.

[36]  D. Vignali.  Multiplexed particle-based flow cytometric assays. , 2000, Journal of immunological methods.

[37]  W. White,et al.  Quantitative Disassembly and Reassembly of Human Papillomavirus Type 11 Viruslike Particles In Vitro , 1998, Journal of Virology.

[38]  J. Dillner,et al.  Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. , 1996, Virology.

[39]  L. Gissmann,et al.  Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae. , 2000, Human gene therapy.

[40]  D. Lowy,et al.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype , 1996, Journal of virology.

[41]  S Wacholder,et al.  Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. , 1993, Journal of the National Cancer Institute.

[42]  I. Frazer,et al.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. , 1991, Virology.

[43]  R. Schlegel,et al.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J R Kettman,et al.  Multiplexed analysis of human cytokines by use of the FlowMetrix system. , 1998, Clinical chemistry.

[45]  D. Lowy,et al.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope , 1997, Journal of virology.

[46]  T. Sasagawa,et al.  Synthesis and assembly of virus-like particles of human papillomaviruses type 6and Type 16 in fission yeast Schizosaccharomyces pombe , 1995 .